SEC Form 4 · accession 0001209191-19-002284
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan J. Watts
Officer — President and CEO · Director
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 6:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jan 2, 2019 | S | 5,050 | $19.42 | D | 2,665,921 | I | See footnote |
| Common StockF4,F3 | Jan 2, 2019 | S | 1,000 | $20.24 | D | 2,664,921 | I | See footnote |
| Common StockF5,F3 | Jan 3, 2019 | S | 6,050 | $18.89 | D | 2,658,871 | I | See footnote |
| Common StockF6,F3 | Jan 4, 2019 | S | 1,300 | $19.18 | D | 2,657,571 | I | See footnote |
| Common StockF7,F3 | Jan 4, 2019 | S | 4,933 | $20.02 | D | 2,652,638 | I | See footnote |
| Common Stock | holding | — | — | — | 12,505 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F2The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.04 to $19.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- F4The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.09 to $20.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.56 to $19.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F6The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.72 to $19.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F7The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.75 to $20.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.